Disabled macroautophagy

Autophagy — literally "self-eating" — is the cell's recycling service: it wraps up worn-out proteins and broken organelles, digests them, and reuses the parts. It is thought to slow with age, letting the cellular garbage behind neurodegeneration, heart failure and sarcopenia accumulate — and while exercise raises its markers in human muscle and fasting switches it on in animals, nobody can yet measure whether it is working in a person's tissues.

Disabled macroautophagy is the fifth of the twelve hallmarks of aging and one of the newest, promoted to a standalone hallmark when the framework was expanded from nine to twelve in 2023.[1] Until that 2023 revision it was counted inside loss of proteostasis; it was split out because autophagy clears not just proteins but entire organelles and other large cargo, and its decline is a distinct, central driver of age-related disease.[2] Macroautophagy (hereafter just autophagy) is a conserved catabolic process: damaged organelles, misfolded protein aggregates, and even invading pathogens are sequestered inside a double-membraned vesicle, the autophagosome, which fuses with a lysosome — the cell's acid-filled digestive compartment — so the cargo is broken down and recycled into amino acids and fatty acids.[3] It is one of three autophagy routes, alongside microautophagy, in which the lysosome swallows cargo directly, and chaperone-mediated autophagy, which handles only individual proteins tagged for it. Macroautophagy is the high-capacity arm and the main route for bulky aggregates and whole organelles.[4]

How confident should you be

Descriptive — Strong. Intervention — Moderate for exercise, Weak for fasting and for every drug and supplement. Caution on chronic rapamycin.

The machinery is well characterised and its decline with age is well documented in animals, though not yet in people, and the disease links are supported by genetic experiments in animals rather than association alone. That exercise induces autophagy is Moderate — it rests on human muscle biopsies, unusually good evidence for this field, though the endpoint is a molecular marker rather than a health outcome. That fasting does so in humans is Weak: human studies have found inconsistent or no changes in autophagy markers, and no fasting length is known to switch it on. That any drug or supplement usefully restores autophagy in healthy people is Weak: rapamycin is the most reproducible drug lifespan-extender in animals and has never been shown to extend life or slow aging in healthy humans. And the whole area carries a measurement caveat that has no equivalent elsewhere in this pillar: autophagic flux can only be measured in cells taken out of the body, mostly blood cells, not in the brain, heart or muscle where it matters most, so no intervention here can be confirmed to be working in anyone's tissues.

The machinery: how a cell eats itself, step by step

Autophagy is orchestrated by a cascade of more than thirty autophagy-related (ATG) proteins acting in sequential phases, and knowing the players makes the interventions legible.[5]

Initiation. The trigger is the ULK1 complex (a protein-kinase complex named for Unc-51-like kinase 1), which switches the process on and recruits a second complex built around a lipid kinase and the protein Beclin-1. Together they nucleate a cup-shaped membrane, the phagophore — the seed of the autophagosome.

Elongation. The phagophore grows around its cargo via two ubiquitin-like "tagging" systems: one built on a protein complex, and the conversion of a cytosolic protein, LC3-I, into its lipid-anchored form LC3-II, which embeds in the growing membrane.[6] LC3-II stays bound to the finished autophagosome, which is why it is the standard molecular marker that autophagy is actually running.

Selective targeting and degradation. Autophagy is not just bulk disposal — it can be selective, recognising cargo flagged with ubiquitin tags. A receptor protein, p62/SQSTM1, bridges the tagged junk to the LC3 on the membrane and drags it into the vesicle. The sealed autophagosome then fuses with a lysosome, whose acid enzymes dismantle the cargo.[7] The best-studied selective form is mitophagy, the targeted removal of damaged mitochondria, whose failure is central to mitochondrial dysfunction.

The whole program is also controlled at the transcriptional level by a master regulator, transcription factor EB (TFEB), which when active travels to the nucleus and switches on the entire suite of autophagy and lysosome genes — making it a key target for reversing age-related autophagic decline.[8]

The control panel: nutrient sensing decides when to recycle

Whether autophagy runs is set by the same nutrient-sensing network that defines the deregulated nutrient sensing hallmark, through two opposing master switches.[9]

mTORC1 is the brake. When nutrients are plentiful — amino acids, growth factors — the mechanistic target of rapamycin complex 1 (mTORC1) is active and phosphorylates ULK1 at an inhibitory site, keeping the cascade off and TFEB out of the nucleus. Fed cells don't recycle; they grow.

AMPK is the energy sensor. When energy runs low (a high ratio of AMP to ATP, the cell's "low battery" signal), AMP-activated protein kinase (AMPK) switches on and suppresses mTORC1, releasing the brake on autophagy. Whether it also presses the accelerator directly is now disputed: in cell experiments, an acute energy shortage led AMPK to hold back the starter kinase ULK1 rather than switch it on, apparently to save energy while keeping the machinery intact for when the stress passes.[10][11] A 2025 review describes AMPK as playing a dual role in autophagy rather than acting as a simple trigger.[12] This low-energy signalling is part of why fasting and exercise can induce autophagy, and why so many longevity interventions converge here. Aging may also blunt the sensor: in old rats, AMPK activity at rest in skeletal muscle matched that of young rats, but its response to exercise or a drug activator was blunted.[13][14] Whether this slows autophagy in older people has not been measured.

A further layer comes from the sirtuins. SIRT1 is an enzyme that depends on nicotinamide adenine dinucleotide (NAD⁺), a coenzyme essential to energy production and repair. In cell and mouse studies it strips acetyl tags directly off core autophagy proteins (Atg5, Atg7 and Atg8), and cells lacking it cannot fully switch autophagy on when starved.[15] That links the cell's energy and redox state to recycling, and connects autophagy to the NAD⁺ biology covered under mitochondrial dysfunction.

Why it fails with age

Moderate — and the failure point may not be where it is usually assumed to be.

The consequences of declining autophagy fall hardest on post-mitotic tissues — neurons and heart-muscle cells — that cannot divide to dilute their accumulated damage the way replicating cells can.[16] In a young cell, brisk autophagic flux continuously clears oxidised proteins, aggregates and spent organelles, and in most animal studies autophagy declines with age, letting that material build up. For the normal human brain, though, the evidence is only indirect, mostly from gene-expression studies, because flux cannot be measured properly in tissue taken after death.[17] One of the few human signals comes from body fluids: levels of ULK1, the enzyme that starts autophagy, were lower at older ages in the blood and spinal fluid of 75 cognitively healthy adults and were also reduced in 316 people with Alzheimer's, and raising ULK1 in Alzheimer's mice stepped up autophagy and reduced amyloid and tau damage; a fluid marker is not a direct measure of autophagy in the brain, though.[18] The first direct measurements in living people's cells also complicate the simple story. In a small study of immune T cells from healthy adults, flux was higher in donors aged 67 to 93 than in those aged 23 to 35.[19] In blood cells, flux rose with age in 114 adults at higher risk of type 2 diabetes, and in a healthy-aging cohort higher blood-cell flux in people over about 70 went with poorer physical function, while in skin cells it fell with age in men but not in women.[20][21] One reading is that aging cells push recycling harder to cope with more damage, so a higher number in an older person is not necessarily a good sign. The failure point may not be the building of autophagosomes but the final lysosomal step. In brain tissue from people with Alzheimer's, immature autophagosomes pile up in swollen, damaged nerve branches, which suggests they stall on the way to the lysosome,[22] and in five mouse models of Alzheimer's the compartments that digest autophagy cargo lose their acidity inside neurons well before amyloid plaques appear; the worst-hit neurons fill with undigested vesicles in a pattern also seen in human Alzheimer's brain.[23] The picture is a traffic jam (autophagy switched on harder while digestion fails) rather than a shortage.[24] These vesicles are rare in brains without Alzheimer's changes, so whether the same holds in ordinary aged tissue is not established.

Where the failure shows up: the diseases of stalled recycling

Strong for neurodegeneration, where animal genetics establish direction (though no autophagy-boosting drug has yet helped patients); Moderate for the heart, liver and muscle links.

Neurodegeneration is the clearest case. The brain's inability to clear aggregation-prone proteins is central to its major diseases: failing autophagy lets amyloid-beta and hyperphosphorylated tau accumulate in Alzheimer's, alpha-synuclein in Parkinson's, and mutant huntingtin in Huntington's.[25] The causal direction has been shown in mice: animals engineered to lose a core autophagy gene (Atg7) in forebrain neurons after birth develop age-dependent neurodegeneration with a build-up of phosphorylated tau, though not the tangles of human disease. Deleting tau or blocking its phosphorylation significantly reduced the nerve-cell damage, even though the protein clumps left by failed autophagy remained.[26] Alzheimer's-linked molecules also converge on this pathway: amyloid-beta and the APOE4 gene variant (the commonest genetic risk factor for late-onset Alzheimer's) both disturb autophagy in lab studies, brain support cells carrying APOE4 clear cargo more slowly, and people with Alzheimer's who carry APOE4 show low levels of two autophagy markers.[27] In cultured mouse nerve-derived cells, APOE4 makes amyloid-beta-induced lysosome leakage worse.[28] And in cell and mouse studies, losing the presenilin enzymes (which are mutated in early-onset familial Alzheimer's) disrupts lysosome function, though laboratories still disagree on whether the cause is lysosomes that cannot acidify properly or faulty calcium handling.[29][30][31] Crucially, the timing of any intervention matters: in advanced disease where the lysosome is already broken, simply making more autophagosomes may backfire, piling up undigested vesicles.[32] So far, human trials have not borne out the animal results. In a randomised, placebo-controlled trial in 161 adults with amyotrophic lateral sclerosis (ALS, motor neurone disease), weekly intravenous trehalose, a sugar chosen because it switches on autophagy in animal models, did not clearly slow decline over 24 weeks: progression was about 13% slower on paper, well within the range of chance, no secondary measure improved, and serious side effects were more than twice as common as on placebo (16% versus 7%).[33] Getting drugs into the brain is a further hurdle: in a small pilot without a placebo group in 10 older adults with mild cognitive impairment or early dementia, rapamycin at 1 mg a day for eight weeks never reached detectable levels in the fluid around the brain, did not change cognition, and markers of brain injury and tau rose rather than fell, though disease progression may explain the rise.[34]

Heart. Cardiomyocytes depend heavily on autophagy and mitophagy to survive their relentless workload, and in animal studies baseline cardiac autophagy falls with age.[35] In mice, switching off a core autophagy gene in the adult heart leads to a thickened, weakened heart and an early, aging-like heart-muscle disease, but forcing autophagy too high under heavy pressure load also worsened damage, so balanced flux is the goal rather than as much autophagy as possible.[36] Human evidence is thinner and harder to read. In hearts removed at transplant from 19 people with severe dilated cardiomyopathy, a small fraction of heart-muscle cells (about 0.08%) held build-ups of ubiquitin-tagged protein alongside autophagic vacuoles; the authors traced this mainly to faults in the cell's other disposal system, the proteasome pathway, with a halving of the lysosomal enzyme cathepsin D as a possible extra factor, and read it as autophagic cell death.[37] Reviews read this and similar human findings as more autophagy rather than less, and it is unclear whether that is a failed rescue attempt or part of the damage.[38]

Liver and metabolism. The liver uses autophagy to break down both proteins and fat — the latter via lipophagy, the autophagic digestion of lipid droplets. In mice, blocking it makes fat build up in the liver (hepatic steatosis).[39] Obesity in turn suppresses liver autophagy: in obese mice it was sharply reduced, and restoring a core autophagy gene in the liver improved the liver's response to insulin and blood-sugar control, so the vicious cycle is shown causally only in animals.[40] Liver biopsies from people with fatty liver disease show signs of stalled recycling, more marked in the inflamed form (non-alcoholic steatohepatitis) than in simple fatty liver.[41]

Muscle. Age-related autophagic decline is closely tied to sarcopenia — the loss of muscle mass and strength. Beyond clearing damaged components from muscle fibres, autophagy also keeps the muscle's stem cells, the satellite cells, healthy. In mice, when it fails with age or is switched off genetically, these cells slip into senescence instead of repairing tissue, and restoring autophagy reversed this in very old mice; autophagy is also lower in satellite cells from very old people.[42] Whether this blunts the human response to exercise has not been tested.[43]

Moderate — well-mapped mechanism, largely from cells and animals.

Failing autophagy doesn't just let junk pile up inside cells — it actively stokes the body-wide inflammation of aging. When mitophagy can't keep up, damaged mitochondria leak their contents — reactive oxygen species and mitochondrial DNA — into the cytoplasm, where they act as danger signals that trigger the NLRP3 inflammasome, a molecular alarm that releases the potent inflammatory messengers interleukin-1β and interleukin-18.[44] Healthy mitophagy normally restrains this alarm by clearing damaged mitochondria before they can set it off: mouse immune cells lacking key autophagy genes carry more damaged mitochondria and release more interleukin-1β.[45] That makes failing autophagy a plausible route into inflammaging, although it has been mapped mainly in cells and mice.[46]

The relationship with cellular senescence is genuinely two-faced. Healthy autophagy suppresses the slide into senescence by clearing the damage that would otherwise trip the cell's stress alarms, but once a cell is senescent it can also help the cell make the inflammatory proteins it secretes, the senescence-associated secretory phenotype (SASP).[47] In cultured cells, blocking autophagy delayed senescence, including that secretion.[48] The practical implication is that autophagy is unambiguously protective in young, healthy tissue, but the goal in age is restoring physiological flux rather than maximising autophagy everywhere at all costs.

Autophagy also props up the immune system itself. In mice, T cells lacking it carry a heavy load of damaged mitochondria and fail to form long-lived memory cells.[49] In aged mice, T-cell autophagy is already low, and the autophagy-inducing compound spermidine revived their T-cell responses.[50] The human evidence so far is correlational: in older vaccine recipients, T cells with less autophagy responded more weakly, and T cells from old donors regained autophagy and function when given spermidine in the lab.[51]

How to switch it back on

Moderate for exercise; Weak for fasting in humans, and Weak for the supplements and drugs.

Fasting and caloric restriction are the most robust inducers in animals. Lowering nutrient availability suppresses mTORC1 and activates AMPK and SIRT1, releasing the brake on the autophagic machinery; the longevity benefits of caloric restriction across species are thought to be mediated substantially by this.[52] The mechanism reaches down to specific metabolites: fasting depletes the cell's pool of acetyl-CoA, switching off an enzyme (EP300) that otherwise keeps autophagy proteins acetylated and inactive.[53] Fasting also raises the body's own spermidine, which has been measured in yeast, flies, mice and human volunteers. Blocking spermidine production blunted fasting-triggered autophagy in yeast, worms and human cells and cancelled fasting's lifespan benefit in animals; spermidine works through a chemical tag on the protein eIF5A that boosts production of the master regulator TFEB. Whether this chain matters for autophagy in people is not yet shown.[54][55] In people the evidence is thin. Studies of 24- to 72-hour fasts have found inconsistent changes in autophagy markers in muscle and blood, a study of 24- and 48-hour water fasts in 9 healthy adults found no rise in the actual rate of recycling in white blood cells after 24 hours, and how long a person must fast to switch autophagy on is unknown; the popular "24 to 72 hours" figure comes from mouse studies.[56] In 50 middle-aged women with obesity who fasted for 24 hours three days a week for eight weeks, autophagy markers in thigh muscle showed no sign of activation (one rose after a 24-hour fast, several fell with weight loss).[57] The best randomised result so far is modest: in 121 adults with obesity, six months of intermittent fasting plus time-restricted eating left autophagic flux in blood cells higher than in a standard-care group, but only in an exploratory analysis, with no significant rise within the fasting group itself and no effect from plain calorie restriction.[58] Extreme restriction that tips into malnutrition can harm immune function,[59] so a sustainable pattern such as time-restricted eating is the sensible default, though it has not been shown to raise autophagy in people either.

Exercise is a powerful inducer, with some human data. In muscle biopsies from 12 moderately trained young men, the autophagy marker LC3-II was about 1.5 to 2 times its starting level two hours after an hour of cycling, and the mitophagy marker BNIP3 was also higher; after eight weeks of training their resting muscle held more of the proteins that regulate autophagy, though not more autophagosomes. These are snapshots of marker levels, not a measured recycling rate.[60] Whether autophagy is needed for the benefits of training has been tested only in mice: mice with one working copy of the autophagy gene Beclin-1 gained less mitochondrial content, blood-vessel growth and endurance from wheel running.[61] In older people the picture is less simple: in a pilot of five adults aged 77 to 88, twelve weeks of mild exercise improved physical function while autophagic flux in their blood cells fell.[62] This connects directly to the zone 2 and resistance training evidence elsewhere on the site.

Caloric-restriction mimetics are drugs and compounds that aim to reproduce these effects, and the site covers the clinical detail under geroprotectors. Spermidine (a dietary polyamine in wheat germ, mature cheese, mushrooms and fermented soy) has an observational case. In one cohort of 829 adults aged 45 to 84 in northern Italy, people in the top third of intake had about 39% lower death rates from any cause than those in the bottom third, though the link weakened once overall diet quality was accounted for.[63] The trial the field wanted came back null. In 100 adults aged 60 to 90 with subjective cognitive decline, 12 months of a spermidine-rich wheat-germ extract (about 0.9 mg of spermidine a day) improved neither memory nor the biomarkers compared with placebo; the authors themselves flag the low dose.[64] Absorption may be part of the problem: in 12 healthy volunteers, 15 mg a day by mouth for 5 days raised blood spermine but not spermidine.[65] A 2026 pilot in 40 adults over 65 found that 6 mg a day for 13 weeks raised autophagy-gene activity in B cells (a type of immune cell), and improved vaccine responses only in people who had responded poorly before; it is small, unconfirmed and run by authors who consult for spermidine sellers.[66] Resveratrol is often sold as a SIRT1 activator, but how it works is disputed: the early lab signal depended on an artificial fluorescent tag on the test molecule and vanished without it,[67] work in mice points to an indirect route through the cell signal cyclic AMP and AMPK,[68] and other researchers argue it activates SIRT1 directly with certain natural substrates.[69] Either way, very little of an oral dose reaches the blood. Metformin activates AMPK. And rapamycin directly inhibits mTORC1 — the most reproducible pharmacological lifespan-extender in animal models. Urolithin A, which gut bacteria make from compounds in pomegranates and walnuts, is sold as a mitophagy activator, meaning it is supposed to speed up the clearance of damaged mitochondria. Its human trials have mostly missed their main targets. In 66 adults aged 65 to 90, four months of it did not improve walking distance or muscle energy production,[70] and a 2026 systematic review of five trials (236 people) could pool walking distance from only two of them, found no clear gain, and rated the evidence low certainty.[71] A manufacturer-funded trial in 50 healthy middle-aged adults reported a small rise in "naive-like" CD8 T cells, a fresher-looking type of immune cell, after four weeks.[72] None of these trials measured mitophagy itself.

The honest gaps: rapamycin's translational problem and the tissue-biomarker gap

Weak, and Caution on chronic use: glucose intolerance, impaired wound healing and immunosuppression are documented at higher or sustained doses.

Rapamycin extends lifespan in yeast, worms, flies, and mice, where mid-life dosing delays multiple age-related diseases.[73] Translating that to healthy humans is genuinely unsettled. The largest and longest randomised trial in healthy adults, PEARL, gave people aged 50 to 85 placebo or 5 or 10 mg of compounded rapamycin once a week for 48 weeks. The drug looked relatively safe, but it missed its main goal (belly fat did not change), its few positive results were in small subgroups or were matched by the placebo group, and the compounded pills turned out to reach only about a third of the blood level of standard rapamycin.[74] The often-quoted immune benefit, a roughly 20% better flu-vaccine response in older volunteers, came from a related drug, everolimus, not rapamycin.[75] A small 2026 trial adds a caution for anyone combining the drug with training: in 40 sedentary adults aged 65 to 85 on a 13-week home exercise programme, adding 6 mg of rapamycin once a week did not improve their gains in a chair-stand test, a secondary analysis of those who followed the protocol suggested it may have blunted them slightly, and there were more adverse events on the drug (99 versus 63 events, though 85% of people in each group had at least one); the authors called the trial exploratory.[76] Long-term use in transplant and epilepsy patients brings impaired wound healing and more infections, and rapamycin can cause glucose intolerance.[77] A 2025 review of the human trials reached the same verdict: none has shown that rapamycin extends life or delays age-related disease in people, and the evidence is not enough either to confirm or to rule out the benefits claimed for it.[78] It is firmly investigational, not a routine intervention.

Underlying all of this is a measurement problem. The usual readouts (LC3-II and p62 levels in accessible cells) are static snapshots, not rates, and a high level of autophagy markers can mean either brisk recycling or a blockage where autophagosomes pile up undigested. The one practical rate measurement is a blood test: a fresh sample is split, half is treated with a drug that stops lysosomes digesting, and the extra LC3-II that builds up in immune cells over a set time gives the flux.[79] It is now used as the main outcome of randomised trials; in one crossover trial in 63 healthy young adults (average age about 30), four weeks with protein cut from 20% to 10% of calories did not change blood-cell flux.[80] But the measurement happens outside the body and captures only blood cells, and in aged mice blood-cell flux did not match the heart or brain, so it cannot tell you what your muscles or neurons are doing.[81] For rapamycin there is also no standard marker of whether the drug is actually suppressing mTORC1 in a given person.[82] Without a measure in the tissues that matter, no intervention can be confirmed to be working in anyone's muscles or brain. The few human fasting studies that have measured flux use white blood cells as a stand-in, and their results are tentative. Besides the exploratory time-restricted-eating result above, a small pilot of a fasting-mimicking diet in 30 healthy adults, funded by the diet's maker, found that blood-cell autophagic flux trended higher than in controls at the end of the six-day diet, but the difference was not statistically significant; the significant change was in a static marker, and the control group was leaner at the start.[83] A trial with flux as its main outcome, a three-day water-only fast with or without glycogen-depleting exercise in 24 adults, has published its protocol but not its results,[84] and an earlier registered trial meant to track fasting-induced autophagy in fat and blood cells was withdrawn without enrolling anyone.[85]

What this does and doesn't tell you

What it tells you: autophagy is a real, mechanistically detailed quality-control system whose decline is causally tied to neurodegeneration in animal genetics, and linked, mostly in animal studies, to heart failure, metabolic disease, sarcopenia and inflammaging — and whose control panel (mTORC1, AMPK, SIRT1, TFEB) is exactly the one that fasting, exercise, and the leading geroprotectors act on. That convergence, plus genuine human muscle-biopsy data showing exercise raises autophagy markers, is why "switching on autophagy" is a credible throughline connecting several of the best-evidenced interventions on this site.

What it doesn't tell you: that more autophagy is always better (the senescence duality and the lysosomal-bottleneck problem say otherwise), that any supplement is a proven human autophagy therapy (spermidine has the best epidemiological case, but its one long trial was null), that rapamycin is ready for healthy adults (it isn't), or even that we can yet confirm an intervention is working in a given person (the flux-biomarker gap is real). The durable message: the recycling system is genuinely central, and the best-supported way to support it is exercise — the one lever with human muscle-biopsy data behind it — alongside the familiar metabolic levers of fasting and a diet that doesn't keep mTOR switched on around the clock.

Further reading

  • López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023.[86]
  • Kaushik S, et al. Autophagy and the hallmarks of aging. Ageing Res Rev 2021.[87]
  • Barbosa MC, Grosso RA, Fader CM. Hallmarks of aging: an autophagic perspective. Front Endocrinol (Lausanne) 2018.[88]
  • Alfaro IE, et al. Chaperone mediated autophagy in the crosstalk of neurodegenerative diseases and metabolic disorders. Front Endocrinol (Lausanne) 2018.[89]
  • Nieto-Torres JL, et al. Macroautophagy and aging: the impact of cellular recycling on health and longevity. Mol Aspects Med 2021.[90]
  • Martinez-Lopez N, et al. Autophagy and aging. Adv Exp Med Biol 2015.[91]
  • Nakamura S, Yoshimori T. Autophagy and longevity. Mol Cells 2018.[92]
  • Lior N, et al. The connection between autophagy and Alzheimer's disease. Inflamm Res 2025.[93]
  • Inoue K, et al. Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol Neurodegener 2012.[94]
  • Woodall BP, Gustafsson ÅB. Autophagy – a key pathway for cardiac health and longevity. Acta Physiol (Oxf) 2018.[95]
  • Sebastián-Valverde M, Pasinetti GM. The NLRP3 inflammasome as a critical actor in the inflammaging process. Cells 2020.[96]
  • Brandt N, et al. Exercise and exercise training-induced increase in autophagy markers in human skeletal muscle. Physiol Rep 2018.[97]
  • Lira VA, et al. Autophagy is required for exercise training-induced skeletal muscle adaptation and improvement of physical performance. FASEB J 2013.[98]
  • Mariño G, Pietrocola F, et al. Caloric restriction mimetics: natural/physiological pharmacological autophagy inducers. Autophagy 2014.[99]
  • Roark KM, et al. Rapamycin for longevity: the pros, the cons, and future perspectives. Front Aging 2025.[100]
  • Hands JM, et al. What is the clinical evidence to support off-label rapamycin therapy in healthy adults? Aging (Albany NY) 2025.[101]

— § —